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Id protein family consists of four members namely Id-1 to Id-4. Different from other basic helix–loop–helix transcription factors, they
lack the DNA binding domain. Id proteins have been shown to be dysregulated in many different cancer types and their prognostic
value has also been demonstrated. Recently, Id-1 has been shown to be upregulated in oesophageal squamous cell carcinoma
(ESCC). However, the prognostic implications of Id proteins in ESCC have not been reported. We examined the expression of the Id
proteins in ESCC cell lines and clinical ESCC specimens and found that Id protein expressions were dysregulated in both the ESCC
cell lines and specimens. By correlating the expression levels of Id proteins and the clinicopathological data of our patient cohort, we
found that M1 stage tumours had significantly higher nuclear Id-1 expression (P¼0.012) while high nuclear Id-1 expression could
predict development of distant metastasis within 1 year of oesophagectomy (P¼0.005). In addition, high levels of Id-2 expression in
both cytoplasmic and nuclear regions predicted longer patient survival (P¼0.041). Multivariate analysis showed that high-level
expression of Id-2 in both cytoplasmic and nuclear regions and lower level of nuclear Id-1 expression were independent favourable
predictors of survival in our ESCC patients. Our results suggest that Id-1 may promote distant metastasis in ESCC, and both Id-1 and
Id-2 may be used for prognostication for ESCC patients.
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Oesophageal cancer is the eighth most common cancer and the sixth
most common cause of cancer-related death worldwide with a 20-fold
higher risk being observed in China when compared to other low-risk
areas (Parkin et al, 2005). While the incidence of oesophageal
adenocarcinoma in western countries is increasing, the predominant
type of oesophageal cancer is still squamous cell carcinoma (Lam, 2000).
Id protein family is a group of helix–loop–helix transcription
factors that have been implicated in different steps in carcinogenesis
such as tumorigenesis, differentiation and metastasis (Benezra
et al, 2001; Zebedee and Hara, 2001; Hasskarl and Munger, 2002;
Sikder et al, 2003; Fong et al, 2004; Wong et al, 2004). Recent
studies exploring the potential use of Id proteins as tumour
markers have revealed that they play different roles in different
types of cancer such that they might act as markers for
progression, metastasis and prognosis in some cancer types. For
instance, a high-level expression of Id-1 has been shown to be
associated with poor prognosis of early-stage cervical cancer
(Schindl et al, 2001), node-negative breast cancer (Schoppmann
et al, 2003) and malignant melanoma (Straume and Akslen, 2005).
Id-1 has also been shown to promote metastasis through
increasing invasiveness and angiogenesis in breast and prostate
cancer (Fong et al, 2003; Ling et al, 2005). High level of Id-2 has
been demonstrated to reduce breast cancer cells invasiveness and
therefore could act as a favourable prognostic marker for breast
cancer patients (Stighall et al, 2005). In addition, the methylation
status of Id-4 has been shown to correlate with poor prognosis in
colorectal cancer (Umetani et al, 2004). Taken together, these
results suggest that Id proteins are important in cancer initiation
and progression, and that they may be useful prognostic markers.
Id-1 has been shown to be overexpressed in oesophageal squamous
cell carcinoma (ESCC) (Hu et al, 2001). A recent study on functional
roles of Id-1 in ESCC revealed that expression of Id-1 increased
proliferation and decreased TNF-a-induced apoptosis in ESCC cell lines
(Hui et al, 2006). These results suggest that Id-1 plays an important role
in tumorigenesis of ESCC. However, the prognostic significance of Id-1
has not been adequately studied, and the expressions of other members
of Id protein family in ESCC remain to be elucidated.
MATERIALS AND METHODS
Patients and specimens
The patient cohort consists of 84 ESCC Chinese patients who had
undergone total oesophagectomy for ESCC in Queen Mary
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sHospital from 1998 to 2005. The clinical data collected prospec-
tively are summarised in Table 1. Briefly, the patients recruited to
this study had not received any chemoradiotherapy directed
against ESCC prior to oesophagectomy. The oesophagectomy
specimens were processed for routine histopathologic diagnosis.
Tissue blocks were fixed in 10% buffered formalin overnight and
then processed for paraffin embedding. Non-neoplastic oesopha-
geal epithelium was selected from the upper resection margin of
the oesophagectomy specimens. Clinical stage at the time of
operation was classified according to the TNM staging system,
while tumour grades were classified based on the World Health
Organization classification (Hamilton and Aaltonen, 2000).
Patients who developed distant metastasis within 1 year of
oesophagectomy were regarded to have ESCC of high metastatic
potential, while those who did not were considered to have ESCC
of low metastatic potential. The median follow-up of our patient
cohort is 12.6 months (ranged from 0.7 to 65.1 months).
Cell lines
Immortalise oesophageal epithelial cell line NE1 was maintained in
KSFM (Invitrogen, Carlsbad, CA, USA). ESCC cell lines EC18,
EC109 and KYSE70 were maintained in RPMI-1640 (Invitrogen)
with 10% FBS. HKESC2 was maintained in MEM (Invitrogen) with
20% FBS. KYSE30 and KYSE150 were maintained in 1:1 RPMI-
1640/Ham’s F12 medium with 10 and 2% FBS, respectively.
Western blotting
Western blotting was performed as previously described (Kwok
et al, 2005) using primary antibodies against Id-1 and Id-2 (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) at a concentration of
1:500 and 1:200, respectively. Actin was used as a loading control
by using anti-actin antibody (Sigma, St Louis, MO, USA).
Tissue microarray construction
Tissue microarray (TMA) was constructed with a Beecher
Instruments tissue microarraryer (Beecher Instruments, Silver
Spring, MD, USA). Three representative areas of each specimen,
including 33 non-neoplastic oesophageal epithelium and 84 ESCC
specimens, were selected by a pathologist (K-W Chan) and
transferred to a TMA block using a 0.6mm core diameter needle.
Haematoxylin- and eosin-stained sections from each TMA block
were checked by K-W Chan to ensure that adequate targeted areas
had been included. The sample numbers varied slightly among
staining results due to a variation in the number of interpretable
specimens on TMA sections.
Immunohistochemical staining
Immunohistochemical staining using Dako EnVisionþ system-
HRP (Dako Corporation, Glostrup, Denmark) was carried out
according to the manufacturer’s instructions. Polyclonal anti-Id-1
(C-20), Id-2 (C-20), Id-3 (C-20) and Id-4 (H-70) antibodies
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) were applied
at a 1:600, 1:800, 1:200 and 1:50 dilution, respectively, for
overnight incubation at 41C. For peptide-blocking analysis used to
verify antibody specificity, five-fold (w/w) excess of blocking
peptide (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was
preincubated with the corresponding primary antibody overnight
at 41C before applying them to the TMA slides.
Evaluation of immunohistochemical staining results
The stained sections were reviewed by two independent observers
(K-W Chan and Y-P Chan) who had no prior knowledge of the
clincopathological data of the patient cohort. The ‘hot spot’
method was employed in evaluation of the staining results. All
three cores of each specimen in the TMA were individually scored,
and the highest score was selected for later statistical analysis. The
extent and intensity of cytoplasmic staining was graded by an
arbitrary scale ranged from 0 to 3, representing negative (0), weak
(1), moderate (2) and strong (3) staining, respectively. Negative
and weak cytoplasmic staining was classified as low expression,
while moderate and strong cytoplasmic staining was classified as
high expression. Nuclear staining was scored by the percentage of
nuclei positively stained in the whole core with at least 200 nuclei
counted. Specimens with nuclear staining score lower than the
mean percentage were classified as low expression and vice versa.
An overall grade of expression was then assigned by combining
both cytoplasmic and nuclear staining results such that only
specimens having both high cytoplasmic and nuclear staining
scores were graded as high overall staining. Staining patterns other
than that were classified as low overall expression.
Statistical analysis
Statistical analysis was performed using SPSS 14.0 software.
Differences in expression level among different clinicopathological
stages were analysed by w
2 test, Mann–Whitney U-test or Fisher’s
exact test where applicable. The association between expression
level and the risk to develop distant metastasis within 1 year of
oesophagectomy was estimated by odds ratio and 95% confidence
intervals using binary logistic regression analysis. Survival curves
between low- and high-level expressions of the four Id proteins
were estimated by Kaplan–Meier analysis and compared by log-
rank test. Cox regression analysis was performed to identify
independent factors that predict patient survival. All factors with
P-value o0.10 in the univariate analysis were allowed entry to the
multivariate analysis. Backward stepwise selection was used with
removal limits of P-value o0.05. A P-value o0.05 was considered
significant in all the statistical analyses.
Table 1 Patients’ clinical and pathologic features
Number
of cases %
Median
(range)
Age (years) 84 67 (22–87)
Sex
Male 65 77
Female 19 23
T stage
T1 2 2
T2 14 17
T3 51 61
T4 17 20
N stage
N0 31 37
N1 53 63
M stage
M0 69 82
M1 15 18
Histological grade
Well differentiated 13 16
Moderately differentiated 48 57
Poorly differentiated 23 27
Metastatic status 64
Non-metastatic 36 56
Metastatic (within 1 year) 28 44
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Expression of Id-1 and Id-2 in oesophageal cell lines
As shown in Figure 1, Id-1 was detected in four out of six ESCC cell
lines with a high expression in three cell lines investigated. Id-2
was expressed in all six ESCC cell lines and was barely detected in
NE1. These results show that Id-1 and Id-2 are dysregulated in
ESCC as compared to immortalised oesophageal cell line NE1.
In contrast, we found that Id-1 expression was slightly reduced
when the cells were serum-starved. This result suggests that Id-1
expression in ESCC is only slightly affected by the presence or
absence of serum.
Id protein expressions in ESCC and non-neoplastic
oesophageal epithelium specimens
As shown in Figure 2, Id protein expressions were dysregulated in
human ESCC specimens when compared to their non-neoplastic
counterparts. Non-neoplastic oesophageal epithelium expressed a
lower level of Id-1 than the tumour specimens. A majority (85%, 28
out of 33) of non-neoplastic oesophageal epithelium specimens
showed negative cytoplasmic and nuclear Id-1 staining, while
36% (29 out of 80) and 29% (23 out of 80) of ESCC specimens
showed moderate to strong cytoplasmic Id-1 staining and
positive nuclear Id-1 staining, respectively. Both nuclear and
cytoplasmic Id-2 expressions were relatively low in non-neoplastic
oesophageal epithelium with 53% (17 out of 32) of specimens
showed negative to weak staining. However, as many as 87%
(69 out of 79) of ESCC specimens showed moderate to
strong cytoplasmic Id-2 staining and 66% (52 out of 79) showed
positive nuclear Id-2 staining. These results suggest that Id-1 and
Id-2 were differentially expressed in non-neoplastic oesophageal
epithelium and ESCC specimens. In addition, overexpression of
Id-1 and Id-2 might be important in neoplastic transformation
of ESCC.
In contrast, expressions of Id-3 and Id-4 did not differ much
between non-neoplastic epithelium and tumour tissues. Id-3 was
positively detected in 94% (31 out of 33) of non-neoplastic
specimens and in 90% (72 out of 80) of ESCC specimens. While 17
out of 33 (52%) non-neoplastic oesophageal epithelium samples
expressed a low level of Id-4, 36 out of 80 (45%) ESCC specimens
showed similar low expression. Id-3 was mainly expressed in the
nucleus and sometimes in cytoplasm of non-neoplastic oesopha-
geal epithelium, but its expression in ESCC was generally both
cytoplasmic and nuclear. Id-4 was mainly detected in the nucleus
of non-neoplastic oesophageal epithelium samples, while its
expression in cytoplasm is more frequent in ESCC.
Id protein expressions correlated with clinicopathological
parameters
As shown in Figures 2 and 3, we found that primary ESCC at
M1 stage had significantly higher (P¼0.012) nuclear expression
of Id-1 (16.13±7.82%) than those at M0 stage (4.76±1.55%).
Binary logistic regression was then employed to estimate the
odds ratio for patients having high-level nuclear expression of
Id-1 in their primary ESCC to develop distant metastasis within
1 year. Primary ESCC tumours with more than 11.86% (mean
percentage of nuclei stained positive in ESCC specimens) of nuclei
stained positive for Id-1 were regarded as having high and others
as having low nuclear expression. The results showed that patients
with high-level nuclear expression of Id-1 in their primary ESCC
were at a higher risk to develop distant metastasis within 1 year
(odds ratio: 4.615, 95% confidence interval (CI): 1.596 13.348,
P¼0.005).
In contrast, we observed that 59% of primary ESCC at the T4
stage showed a high cytoplasmic Id-1 expression, whereas only
30% of ESCC at the lower T stages with similar staining extent
(Figure 4). By statistical analysis, we demonstrated that high-level
cytoplasmic Id-1 expression was significantly (P¼0.045) asso-
ciated with T4 tumour.
In addition, a statistically significant association was observed
between low-level cytoplasmic Id-2 expression and poor differ-
entiation of the tumour (P¼0.013). While 30% of poorly
differentiated ESCC expressed low-level cytoplasmic Id-2, the
same was observed in only 7% of well or moderately differentiated
tumours (Figure 5). However, expression levels of both Id-3 and
Id-4 were not significantly associated with any of the clincopatho-
logical parameters analysed. These results suggest that dysregula-
tions of Id-1 and Id-2 are involved in tumour progression and
metastasis of ESCC.
To investigate the specificity of Id-1 and Id-2 antibodies in
immunohistochemistry, we performed a peptide neutralisation
analysis. By preincubating the primary antibody with five-fold (w/w)
excess of corresponding blocking peptide, the signal was almost
completely abolished (Figure 6). These results confirmed the
specificity of the antibodies used.
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Figure 1 Western blot analysis of Id-1 and Id-2 expression in
immortalized oesophageal epithelial and ESCC cells. Cancer cells
(2 10
5) were seeded in six-well plate with supplement of serum,
according to the recommendation from the suppliers of the cell lines,
as described in Materials and Methods. Medium was changed after
1 day with either serum-free medium or fresh serum-supplemented
medium NE1 was cultured in KSFM with growth factors supplementation,
and fresh medium was replaced after 1 day. Cells were harvested after
24h. Protein was extracted and the expression level of Id-1 and Id-2
was then compared by Western blot analysis. Note that the expression
of Id-1 was detected in four out of six ESCC cell lines while Id-2
was expressed in all ESCC cell lines tested. (B) The expression level of
Id-1 in three ESCC cancer cell lines with or without serum supplemen-
tation. Id-1 expression level was slightly reduced when the cells were
serum-starved for 24h.
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survival in our ESCC cohorts
By Kaplan–Meier analysis, a high overall grade combining
cytoplasmic and nuclear expression of Id-2 significantly
(P¼0.041) predicted better survival in our cohort (Figure 7).
The mean survival was 28.9 (95% CI: 16.7 41.1) months for
patients with high overall Id-2 expression and 16.8 (95% CI:
12.3 21.1) months for those with low overall Id-2 expression. To
identify independent predictors for survival, univariate and
multivariate Cox-regression analyses were performed. All the
clinicopathological parameters and Id protein expression levels
including age, sex, TNM stage, histological stage, and cytoplasmic,
nuclear and overall Id protein expressions were entered into
Id-1
Id-2
Id-3
Id-4
Figure 2 Representative results of immunohistochemistry of Id-1 to Id-4 expression in oesophageal specimens. (Panel 1) Id-1 expression was negative to
weak in non-neoplastic oesophageal epithelium (A), but increased in ESCC specimens (B–E). While a low level of nuclear Id-1 staining was detected
in primary ESCC at M0 stage (B), a significantly higher level of nuclear Id-1 staining was observed in tumours at M1 stage (C). ESCC at T2 stage (D) had
weak cytoplasmic Id-1 staining while a high-level cytoplasmic Id-1 expression was detected in T4 stage tumour (E). (Panel 2) Id-2 staining was relatively
weak in normal oesophageal epithelium (F) while was higher in tumour specimens (G and H). High level of cytoplasmic Id-2 staining was observed in
well-differentiated tumours (G) but was significantly lower in poorly differentiated tumours (H). (Panel 3) Id-3 staining was high in both normal oesophageal
epithelium (I) and ESCC specimens (J), with mainly nuclear staining in the former one and both cytoplasmic and nuclear staining in the later one.
(Panel 4) Id-4 expression was relatively weak in normal oesophageal epithelium (K) and higher in tumour specimens (L). Image was captured at  400
magnification.
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Figure 3 Nuclear expression of Id proteins in ESCC of different M
stages. Significantly higher nuclear Id-1 expression was detected in M1 stage
tumours when compared to M0 stage tumours (P¼0.012). No significant
association was found between nuclear Id-2, -3 and -4 expression and M
stage.
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Figure 4 Cytoplasmic expression of Id proteins in ESCC of different T
stages. Significantly higher percentage of patients with T4 stage tumour
had a higher cytoplasmic Id-1 expression when compared to patients with
T1–T3 stages tumour (P¼0.045). No significant association was found
between cytoplasmic Id-2, -3 and -4 expressions and T stage.
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(P¼0.007), M1 stage (P¼0.026) and low overall Id-2 expression
(P¼0.045) were significant predictors of poor survival in
univariate analysis (Table 2). Factors with Pp0.10 in univariate
analysis were allowed entry to multivariate Cox-regression
analysis. We found that increasing age (P¼0.017), male sex
(P¼0.019), increasing nuclear Id-1 expression (P¼0.011) and low
overall Id-2 expression (P¼0.020) individually contributed
significantly to poor prognosis as shown by the multivariate
analysis (Table 2).
DISCUSSION
Id proteins have been recently demonstrated to promote cancer
progression and metastasis and are potential prognostic factors in
different types of cancer. In this study, we aimed to investigate how
this knowledge could be applied to further our understanding of
the pathogenesis and progression of ESCC. The expression levels
of Id proteins in ESCC and non-neoplastic oesophageal epithelium
in corresponding oesophagectomy specimens were studied by
immunohistochemistry and the results were correlated with
clinicopathological parameters. We observed that primary
tumours at M1 stage had a significantly higher nuclear Id-1
expression than M0 stage tumours (P¼0.012). A high level of
cytoplasmic Id-1 expression was significantly associated with T4
stage tumour (P¼0.045). In contrast, low-level cytoplasmic Id-2
expression was significantly associated with poorly differentiated
tumours (P¼0.013). In addition, high level of overall Id-2
expression in primary tumour predicted better survival of ESCC
patient in Kaplan–Meier analysis (P¼0.041). By multivariate Cox-
regression analysis, we were able to demonstrate that increasing
nuclear Id-1 expression (P¼0.011) and low overall Id-2 expression
(P¼0.020) were independent predictors of poor overall survival in
our ESCC patients.
Id-1 has been shown to promote metastasis in several different
types of cancer. Overexpression of Id-1 promotes mammary
epithelial cell invasion (Desprez et al, 1998), and reduced
expression of Id-1 in metastatic breast cancer cells leads to a
decrease in invasiveness in vitro (Fong et al, 2003). Overexpression
of Id-1 in prostate cancer cells also promotes metastasis through
increased angiogenesis (Ling et al, 2005) and invasiveness (Coppe
et al, 2004). Reduced expressions of Id-1 and Id-3 have been
demonstrated to inhibit the metastatic ability of gastric cancer cells
(Tsuchiya et al, 2005), and Id-1 expression has been shown to be
associated with the presence of invasion in endometrial carcinoma
(Takai et al, 2001) and tumour angiogenesis in human pancreatic
cancer (Lee et al, 2004). In lines with these results, we found that
primary ESCC at M1 stage had a significantly (P¼0.012) higher
nuclear expression of Id-1 than the M0 stage tumours. In addition,
by binary logistic regression, we observed that a high nuclear
expression of Id-1 in primary ESCC tumours significantly
predicted the development of distant metastasis of the corresponding
patients within 1 year of oesophagectomy (odds ratio: 4.615, 95%
CI: 1.596–13.348, P¼0.005). In addition, a high level of
cytoplasmic Id-1 expression was significantly (P¼0.045) corre-
lated with T4 stage tumours. These results suggest that upregula-
tion of Id-1 in ESCC might promote distant metastasis and cancer
progression. In vitro experiments are being undertaken to
investigate the functional role of Id-1 in metastatic progression
of ESCC.
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Figure 5 Cytoplasmic expression of Id proteins in ESCC of different
histological grades. Significantly higher percentage of patients with poorly
differentiated tumour had a low cytoplasmic Id-2 expression when
compared to patients with well or moderately differentiated tumour
(P¼0.013). No significant association was found between cytoplasmic
Id-1, -3 and -4 expression and histological grade.
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Figure 6 Peptide neutralization of Id-1 and Id-2. (Panel 1) Id-1 staining
was strong in a particular ESCC case (A) but was negative when Id-1
blocking peptide was added (B). (Panel 2) Staining of Id-2 was strong in a
particular ESCC case (C) but was negative when Id-2 blocking peptide was
added (D).
Survival functions
High expression
(N=30)
Low expression
(N=49)
0.8
1.0
0.6
C
u
m
.
 
s
u
r
v
i
v
a
l
0.4
0.2
0.0
0.00 10.00 20.00
Survival time (months)
30.00 40.00 50.00 60.00 70.00
P=0.041
High
High-censored
Low-censored
Low
Figure 7 Kaplan–Meier analysis of Id-2 expression and overall patient
survival. High level of both cytoplasmic and nuclear expression of Id-2
significantly (P¼0.041) predicted better overall patient survival.
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normal murine mammary epithelial cells (Parrinello et al, 2001). In
breast cancer, Id-2 expressed at high levels maintains the cancer
cells in a non-aggressive phenotype (Itahana et al, 2003). In
addition, high level of Id-2 expression has been shown to reduce
the invasiveness of breast cancer cells and can act clinically as a
favourable prognostic marker (Stighall et al, 2005). Similar results
have been obtained in intestinal epithelium where Id-2 promotes
differentiation and inhibit tumorigenesis (Russell et al, 2004). Our
results on Id-2 expression in ESCC also showed that low level of
cytoplasmic Id-2 expression was significantly (P¼0.013) asso-
ciated with poor tumour differentiation. Moreover, high level of
both nuclear and cytoplasmic expression of Id-2 provides
favourable prognosis for our ESCC patients, with mean survival
of 28.9 (95% CI: 16.7–41.1) months when compared to those
having low overall Id-2 expression (16.8 (95% CI: 12.3–21.1)
months).
In the present study, we observed that Id-2 expression was low
in the immortalised oesophageal cell line NE1 and the non-
neoplastic oesophageal epithelium samples showed lower Id-2
expression than their cancer counterparts. These results suggested
that Id-2 promotes neoplastic transformation of oesophageal
epithelial cells. Id-2 has been shown to bind and inhibit the
function of retinoblastoma protein, a tumour suppressor protein
(Iavarone et al, 1994; Lasorella et al, 1996) and therefore has been
implicated in tumour progression in several cancer types
(Maruyama et al, 1999; Fukuma et al, 2003; Coppe et al, 2004).
We speculated that overexpression of Id-2 might promote
neoplastic transformation of oesophageal epithelium through
destruction of the normal cell cycle checkpoint and increased
proliferation. After onset of other oncogenic events, reduced Id-2
expression might increase aggressiveness of ESCC cancer cells
through dedifferentiation and leads to poor patient survival.
To test whether Id-1 and Id-2 might act as independent
prognostic factors in our patient cohort, Cox-regression with
backward stepwise selection was carried out. The results (Table 2)
showed that higher nuclear expression of Id-1 (P¼0.011) and low-
level overall expressions of Id-2 (P¼0.020) were independent
predictors for poor prognosis in our cohort of ESCC patients.
In summary, our results suggest that overexpression of Id-1
can promote neoplastic transformation of normal oesophageal
epithelium, ESCC progression and the development of distant
metastasis. In contrast, expression of Id-2 might inhibit the
emergence of a more aggressive phenotype of ESCC. We provide
new evidence that Id-1 and Id-2 may be useful prognostic
indicators of metastatic potential of ESCC and survival of patients,
respectively.
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